Pomerantz Law Firm Alerts Soleno Therapeutics Investors of Class Action Lawsuit Deadline

Investor Alert: Class Action Lawsuit Against Soleno Therapeutics

Pomerantz LLP, a prominent law firm specializing in class action litigation, has informed investors regarding a class action lawsuit involving Soleno Therapeutics, Inc., whose stock is traded on NASDAQ under the ticker SLNO. Investors who have incurred losses during this period are advised to reach out to the firm to discuss their options and potential participation in the legal proceedings.

Background of the Case

The class action lawsuit raises serious allegations against Soleno Therapeutics and its executives, claiming securities fraud and engaging in other unlawful business practices. Investors who purchased shares of the company’s stock during the designated Class Period have until May 5, 2026, to request appointment as Lead Plaintiff. To participate, affected shareholders are encouraged to contact Danielle Peyton, an attorney at Pomerantz, through the provided email or phone number, ensuring they provide essential details such as their mailing address and telephone number along with the number of shares acquired.

The situation surrounding Soleno has escalated following a report from Scorpion Capital on August 15, 2025. This report characterized Soleno's flagship product, diazoxide choline extended-release tablets (branded as DCCR), as overpriced and potentially hazardous, especially for children. This negative assessment had a swift impact, with the stock price dropping significantly by $5.73, translating to a 7.41% loss, closing at $71.63 per share.

Days later, on September 10, 2025, Soleno publicly disclosed a tragic incident where a patient died after using DCCR. This disclosure led to further losses, causing the stock price to plummet by $13.49, or 19.21%, over the next two trading days, bringing it down to $56.72 per share.

In another troubling development, during a quarterly earnings call on November 4, 2025, Soleno revealed that the discontinuation rate of DCCR due to adverse effects reached approximately 8%. The CEO acknowledged the disruption caused by the Scorpion report, indicating a negative shift in patient acquisition and increased treatment discontinuations.

This revelation resulted in a substantial depreciation of the stock, which fell an additional $16.98, or 26.59%, leading to a closing price of $46.87 on November 5, 2025.

About Pomerantz LLP

Pomerantz LLP has established a distinguished reputation as a formidable player in the realm of corporate, securities, and antitrust class litigation, with a history dating back over 85 years. Founded by Abraham L. Pomerantz, regarded as a pioneer in securities class actions, the firm has been at the forefront of advocating for investors’ rights, recovering millions in damages for class members affected by securities fraud and corporate misconduct.

Their commitment to holding companies accountable and securing justice for investors continues to be a priority. Potential class members seeking further information or wishing to access the Complaint can visit Pomerantz's website.

As this situation unfolds, affected investors are urged to act swiftly to protect their interests and explore their legal options through Pomerantz LLP.

If you have questions about your situation or seek further assistance with this matter, do not hesitate to reach out to Pomerantz LLP. Your rights as an investor matter, and timely action can make a difference.